Use of Atypicals In Major Depression Treatment Is Growing, According to a New Report from Decision Resources Patient-Flow Forecasts Between Pristiq and Effexor XR Need to Take Into Account Reimbursement Hurdles WALTHAM, Mass., May 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that Forest Laboratories' Lexapro is no longer the leading first-line agent of choice for the treatment of major depression.

Sales of hormone replacement therapy have declined recently due to safety concerns, giving non-hormonal drugs for menopausal symptoms an estimated revenue potential of over $535m across the US and five major EU markets in 2007.

COLLEGEVILLE, Pa., Oct. 15 /PRNewswire-FirstCall/ -- Wyeth Pharmaceuticals, a division of Wyeth , today provided an update on its global strategy for desvenlafaxine for the treatment of major depressive disorder (MDD) in adults.

SCOTTSDALE, Ariz., July 21 /PRNewswire/ -- MedPredict Market Research, a global provider of pharmaceutical competitive intelligence and market research, has published a new report providing critical strategic insight for pharma and biotech companies with a stake in the market for anxiety and depression therapies.

WALTHAM, Mass., June 3 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms focusing on pharmaceutical and healthcare issues, finds that, despite physicians' desire to prescribe more serotonin/norepinephrine reuptake inhibitors (SNRIs), Forest Laboratories' Lexapro retains leadership among first-line therapies in the treatment of major depression.